



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Tranexamic Acid-¹³C₂, ¹⁵N Item No. 28804

CAS Registry No.: 1292837-95-6
Formal Name: *trans*-4-(amino-¹⁵N-methyl-¹³C)-cyclohexanecarboxylic-¹³C acid
Synonyms: AMCA-¹³C₂, ¹⁵N, TXA-¹³C₂, ¹⁵N
MF: C₆[¹³C₂]H₁₅[¹⁵N]O₂
FW: 160.2
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tranexamic acid-¹³C₂, ¹⁵N is supplied as a solid. A stock solution may be made by dissolving the tranexamic acid-¹³C₂, ¹⁵N in water. Tranexamic acid-¹³C₂, ¹⁵N is slightly soluble in water. We do not recommend storing the aqueous solution for more than one day.

Description

Tranexamic acid ¹³C₂, ¹⁵N is intended for use as an internal standard for the quantification of tranexamic acid (Item No. 19193) by GC- or LC-MS. Tranexamic acid is an inhibitor of fibrinolysis that inhibits the interaction of plasmin with fibrin (IC₅₀ = 3.1 μM in isolated human plasma).¹ It reduces increases in the expression of the profibrogenic genes *Timp1* and *Col1a1*, but not *Itgb6*, *Tgfb1*, or *Tgfb2*, and increases in hepatic protein levels of cytokeratin 19 (CK19) and type I collagen induced by α-naphthylisothiocyanate (AINT) after 28 days in a mouse model of chronic bile duct injury.²

References

1. Boström, J., Grant, J.A., Fjellström, O., *et al.* Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid. *J. Med. Chem.* **56**(8), 3273-3280 (2013).
2. Joshi, N., Kopec, A.K., Towery, K., *et al.* The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury. *J. Pharmacol. Exp. Ther.* **349**(3), 383-392 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/15/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM